A single dose of CAP-003, a gene therapy being developed by Capsida Biotherapeutic, significantly increased the levels of GCase…
Articles by Margarida Maia, PhD
App-based consumer technology like Rune Labs’ StrivePD may help people with Parkinson’s disease feel more confident in managing…
Exposure to air pollutants, such as fine particulate matter and nitrogen dioxide, may increase the risk of developing Parkinson’s…
GT-02287, a potential therapy for Parkinson’s disease, showed promising results in a Phase 1 clinical trial involving healthy volunteers,…
Patients treated with bemdaneprocel, a cell therapy that Bluerock Therapeutics is developing for Parkinson’s disease, continue to spend…
Pramipexole, the active ingredient in the Parkinson’s disease therapy Mirapex, appears to overactivate a brain region known as…
Parkin, a protein linked to Parkinson’s disease that’s lost in certain types of cancer, triggers the release of signaling…
Ten consecutive weeks of either high-intensity interval training or continuous training, which is moderate in intensity, effectively eased disease…
Subcutaneous, or under-the-skin, injections of COYA 302, a combination therapy in development by Coya Therapeutics, were found to reduce…
Note: This story was updated Sept. 16, 2024, to correct that A-dopamine is a form of dopamine. Levodopa, a…